The 10-second takeaway
For the quarter ended June 30 (Q2), Questcor Pharmaceuticals beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly. GAAP earnings per share expanded significantly.
Gross margins dropped, operating margins grew, net margins grew.
Questcor Pharmaceuticals booked revenue of $184.6 million. The nine analysts polled by S&P Capital IQ expected to see sales of $169.0 million on the same basis. GAAP reported sales were 64% higher than the prior-year quarter's $112.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.12. The six earnings estimates compiled by S&P Capital IQ averaged $0.96 per share. GAAP EPS of $1.12 for Q2 were 72% higher than the prior-year quarter's $0.65 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 90.7%, 360 basis points worse than the prior-year quarter. Operating margin was 55.8%, 150 basis points better than the prior-year quarter. Net margin was 37.5%, 60 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $177.6 million. On the bottom line, the average EPS estimate is $1.04.
Next year's average estimate for revenue is $666.2 million. The average EPS estimate is $3.72.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 505 members out of 558 rating the stock outperform, and 53 members rating it underperform. Among 153 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 131 give Questcor Pharmaceuticals a green thumbs-up, and 22 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Questcor Pharmaceuticals is outperform, with an average price target of $52.44.
- Add Questcor Pharmaceuticals to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.